Chris Buyse

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Creabuild NV provides consulting services. The private company is based in Zaventem, Belgium. The Belgian company was founded in 2005. The CEO is Stéphane Vandervelde.

Sofia BV provides wireless telecommunication services. The private company is based in Knokke-Heist, Belgium. The CEOs are Ann Dendoncker, Chris Buyse, Pieter-Jan Buyse. The Belgian company was founded in 1999.

Pienter-Jan BV is a Belgian company that provides business and management consulting services. The private company is based in Brasschaat, Belgium. The CEO of the company is Ann Dendoncker.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Creabuild NV provides consulting services. The private company is based in Zaventem, Belgium. The Belgian company was founded in 2005. The CEO is Stéphane Vandervelde.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe.

Sofia BV provides wireless telecommunication services. The private company is based in Knokke-Heist, Belgium. The CEOs are Ann Dendoncker, Chris Buyse, Pieter-Jan Buyse. The Belgian company was founded in 1999.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Life Sciences Research Partners VZW functions as a foundation or endowment. The non-profit company is based in Leuven, Belgium. The Belgian company was founded by Désiré Collen.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.